262 related articles for article (PubMed ID: 22436400)
1. Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence.
Cibula D; Skrenkova J; Hill M; Stepan JJ
Eur J Endocrinol; 2012 Jun; 166(6):1003-11. PubMed ID: 22436400
[TBL] [Abstract][Full Text] [Related]
2. Effect of two kinds of different combined oral contraceptives use on bone mineral density in adolescent women.
Gai L; Jia Y; Zhang M; Gai P; Wang S; Shi H; Yu X; Liu Y
Contraception; 2012 Oct; 86(4):332-6. PubMed ID: 22364818
[TBL] [Abstract][Full Text] [Related]
3. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females.
Almstedt HC; Cook MM; Bramble LF; Dabir DV; LaBrie JW
J Bone Miner Metab; 2020 Jul; 38(4):544-554. PubMed ID: 31983034
[TBL] [Abstract][Full Text] [Related]
5. Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period.
Biason TP; Goldberg TB; Kurokawa CS; Moretto MR; Teixeira AS; Nunes HR
BMC Endocr Disord; 2015 Apr; 15():15. PubMed ID: 25990414
[TBL] [Abstract][Full Text] [Related]
6. Combined Oral Contraceptives: Association with Serum 25-Hydroxyvitamin D and Calcium and Bone Homeostasis.
Donangelo CM; Cornes R; Sintes C; Bezerra FF
J Womens Health (Larchmt); 2024 Jun; 33(6):805-815. PubMed ID: 38417038
[No Abstract] [Full Text] [Related]
7. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
8. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
9. Decreased bone turnover in oral contraceptive users.
Garnero P; Sornay-Rendu E; Delmas PD
Bone; 1995 May; 16(5):499-503. PubMed ID: 7654464
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults.
Wattanachanya L; Jantrapakde J; Avihingsanon A; Ramautarsing R; Kerr S; Trachunthong D; Pussadee K; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Phanuphak N; Sunthornyothin S; Phanuphak P;
AIDS Care; 2020 Aug; 32(8):984-993. PubMed ID: 31137948
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.
Wanichsetakul P; Kamudhamas A; Watanaruangkovit P; Siripakarn Y; Visutakul P
Contraception; 2002 Jun; 65(6):407-10. PubMed ID: 12127638
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
13. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
14. Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
Gersten J; Hsieh J; Weiss H; Ricciotti NA
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):635-642. PubMed ID: 27287084
[TBL] [Abstract][Full Text] [Related]
15. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
[TBL] [Abstract][Full Text] [Related]
16. Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.
Nguyen LT; Nguyen UDT; Nguyen TDT; Ho-Pham LT; Nguyen TV
Osteoporos Int; 2018 Dec; 29(12):2739-2744. PubMed ID: 30196375
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.
Cromer BA; Bonny AE; Stager M; Lazebnik R; Rome E; Ziegler J; Camlin-Shingler K; Secic M
Fertil Steril; 2008 Dec; 90(6):2060-7. PubMed ID: 18222431
[TBL] [Abstract][Full Text] [Related]
18. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
[TBL] [Abstract][Full Text] [Related]
19. Low-dose oral contraceptives in adolescents: how low can you go?
Agostino H; Di Meglio G
J Pediatr Adolesc Gynecol; 2010 Aug; 23(4):195-201. PubMed ID: 20227307
[TBL] [Abstract][Full Text] [Related]
20. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
